Want to see MBX full AI Analyst Report?
MBX Stock Chart & Stats
$62.00
-$0.70(-1.13%)
At close: 4:00 PM EDT
$62.00
-$0.70(-1.13%)
Day’s Range― - ―
52-Week Range$9.63 - $72.64
Previous Close$60.9
Volume304.26K
Average Volume (3M)963.99K
Market Cap
$3.23B
Enterprise Value$2.22K
Total Cash (Recent Filing)$418.58M
Total Debt (Recent Filing)$3.34M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 05, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding48,160,095
10 Day Avg. Volume790,850
30 Day Avg. Volume963,994
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$89.50Price Target Upside44.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet / Cash RunwayA multi-year cash runway materially lowers near-term financing pressure and supports completion of Phase 3 and multiple early-stage programs. This durable liquidity gives management time to de-risk key catalysts and pursue clinical readouts without immediate dilution risk, preserving optionality.
Canvuparatide Clinical ProgressRobust Phase 2 and one-year extension efficacy and safety data that support a Phase 3 start constitute structural de-risking for the lead asset. Delivering pivotal trials built on positive OLE results increases the program's probability of success and potential to unlock a durable, commercially relevant therapy.
Obesity Pipeline & Peptide PlatformPromising once-monthly PK for MBX 4291 plus multiple nominated candidates shows the PEP platform can generate differentiated long-acting peptides. Platform-driven pipeline breadth spreads technical risk and creates repeatable product-development economics if one or more candidates advance to later-stage trials.
Bears Say
No Commercial RevenueAbsence of commercial revenue means MBX remains entirely dependent on R&D outcomes and external financing for value creation. Without product sales, operating leverage and margin expansion are unknown, increasing execution risk and making cash runway and trial success the primary drivers of long-term viability.
Sustained Cash BurnPersistent, growing negative operating cash flow and free cash flow indicate real cash consumption to fund trials and infrastructure. Even with current cash, continued high burn raises the probability of future financings, which can dilute shareholders and force timing-sensitive decisions if clinical timelines slip.
Widening Net LossesLarge and increasing operating losses weaken return metrics and can erode equity over time if sustained. This pattern constrains reinvestment capacity absent external capital and magnifies the consequences of any clinical setbacks, since profitability pathways remain entirely contingent on successful commercialization.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $9.63 and its highest was $72.64 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $3.23B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.633 by -$0.147.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.87.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 48,160,095 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.633. Following the earnings report the stock price went down -0.548%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.50 (44.35% Upside)
$89.50 (44.35% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 501.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
375.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
88.28%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$89.50
▲(44.35% Upside)
Technical Analysis
Ownership Overview
25.68% Insiders
15.55% Mutual Funds
10.15% Other Institutional Investors
39.10% Public Companies and
Individual Investors